The current workflow requires physicians to review every examination; the new AI applications aim to automatically identify key ultrasound parameters and present findings to physicians to reduce review time, speed up results, and expand patient reach amid healthcare professional shortages.

Pulsenmore’s home ultrasound platform enables pregnant women to perform physician-prescribed scans at home and transmit images to physicians for review, with over 250,000 scans performed to date.

Investor contact: Miri Segal-Scharia of MS-IR LLC is available for media inquiries.

The press release and SEC filings include standard forward-looking statements about risks and uncertainties related to regulatory compliance, market penetration, IP protection, funding, and operational milestones.

Pulsenmore’s financial snapshot shows a market capitalization around $32 million, revenue growth of about 314% over the past year, a gross margin above 84%, and cash on hand that exceeds debt but ongoing cash burn typical of growth-stage healthcare tech firms.

Pulsenmore has been selected to participate in Israel’s Healthcare AI Regulatory Sandbox Program, funded by the Israel Innovation Authority and the Ministry of Health, to develop and clinically validate AI applications for its home ultrasound platform.

Pulsenmore’s technology has been deployed with Clalit Health Services and other clinical partners worldwide, and the home-scan dataset serves as a foundation for AI development.

The company has a strategic partnership with Ouma Health to integrate its FDA-authorized home ultrasound technology into U.S. virtual maternity care, and recently completed a private placement of roughly $7.5 million to support operations and strategic initiatives.

Dr. Elazar Sonnenschein, Founder and CEO, says the program marks the next evolution of the platform, enabling an AI-powered software layer to improve physician efficiency and expand patient access without sacrificing quality.